Loading news...
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
The consensus price target hints at a 48.6% upside potential for Disc Medicine, Inc. (IRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. (“Disc” or the “Company”) (NASDAQ: IRON). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The U.S. Food and Drug Administration (FDA) reviewers on Thursday postponed their decision on an experimental treatment from Disc Medicine Inc. (NASDAQ: IRON) by about two weeks to Feb.10.
The FDA delays its decision on Disc Medicine's rare disease drug bitopertin, raising review questions. Analysts say the setback is likely minor.
Disc Medicine, Inc. (IRON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Lisa Amaya Price, MBA as the company's Chief Human Resources (HR) Officer. Ms. Amaya Price brings more than 25 years of experience in human resources and organizational leadership, including at multiple commercial-stage companies.
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today outlined its recent pipeline progress and strategic priorities for 2026.
The chief legal officer of Disc Medicine sold 6,500 shares of the company for $511,472 on Jan. 2. The sale represented 14.68% of Khara's direct holdings, as reported at the time, reducing his direct ownership from 44,293 to 37,793 shares.
Disc Medicine, Inc. (NASDAQ: IRON - Get Free Report) insider Rahul Khara sold 6,500 shares of the business's stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $78.69, for a total transaction of $511,485.00. Following the completion of the sale, the insider directly owned 37,793 shares
Disc Medicine is well-capitalized, with over $800M in cash, ensuring operational runway through 2029 regardless of bitopertin's launch success. Bitopertin's NDA is submitted, aiming for accelerated FDA approval; if successful, IRON transitions from R&D to commercial stage with significant revenue potential. Phase 2 data for DISC-0974 in myelofibrosis show strong efficacy, especially in synergy with JAK inhibitors, expanding the addressable market and clinical utility.
Disc Medicine, Inc. (NASDAQ: IRON - Get Free Report) insider William Jacob Savage sold 13,093 shares of the company's stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $91.22, for a total transaction of $1,194,343.46. Following the transaction, the insider owned 75,702 shares in the company, valued at
NEW YORK--(BUSINESS WIRE)--IRON HORSE ACQUISITION II CORP. Announces Pricing of $200 Million Initial Public Offering.
Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript
WATERTOWN, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive initial data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of MF at the ASH Annual Meeting in Orlando, FL. The data demonstrated that treatment with DISC-0974 resulted in substantial reductions in hepcidin and increases in iron levels translating to positive impact on clinically meaningful measures of anemia across a broad range of patient types.
Disc Medicine, Inc. ( IRON ) Jefferies London Healthcare Conference 2025 November 19, 2025 9:00 AM EST Company Participants John Quisel - CEO, President & Director Conference Call Participants Jiale Song - Jefferies LLC, Research Division Presentation Jiale Song Jefferies LLC, Research Division Hello, everyone. Welcome to Jefferies London Healthcare Conference 2025.
Bain Capital completely exited its position in Disc Medicine stock during the third quarter
Disc Medicine, Inc. ( IRON ) Stifel 2025 Healthcare Conference November 13, 2025 8:40 AM EST Company Participants Jonathan Yu - Chief Opearating Officer Conference Call Participants Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Stephen Willey Stifel, Nicolaus & Company, Incorporated, Research Division So we're going to go ahead and get started. I'm Steve Willey, one of the senior biotech analysts here at Stifel.
Shares of Ironveld Plc (LON: IRON - Get Free Report) rose 10% during trading on Friday. The company traded as high as GBX 0.06 and last traded at GBX 0.06. Approximately 259,699,203 shares changed hands during mid-day trading, an increase of 262% from the average daily volume of 71,806,461 shares. The stock had previously closed
WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at three upcoming investor conferences: